Epigenetically acting drugs could support cancer immunotherapy
Epigenetically active drugs enable the cell to read parts oft he genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells. (Source: World Pharma News)
Source: World Pharma News - October 31, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age. (Source: World Pharma News)
Source: World Pharma News - October 30, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101, a novel TL1A directed antibody. (Source: World Pharma News)
Source: World Pharma News - October 27, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Industry payments to physicians linked to use of some non-recommended and low value drugs among cancer patients
Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published by The BMJ.
This finding raises potential concerns about quality of care, and the researchers say it may be appropriate to re-examine the current status of personal payments from the drug industry to physicians. (Source: World Pharma News)
Source: World Pharma News - October 26, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023. (Source: World Pharma News)
Source: World Pharma News - October 25, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Researchers identify & #039;switch & #039; to activate cancer cell death
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die. This new ability to trigger programmed cell death could open the door for improved cancer treatments. The findings were published Oct. 14 in the Nature journal Cell Death & Differentiation. (Source: World Pharma News)
Source: World Pharma News - October 24, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
FDA approves PENBRAYA ™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. (Source: World Pharma News)
Source: World Pharma News - October 23, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
mRNA delivered by extracellular vesicles induces immunotherapy response in glioblastoma
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy. The study was published in Nature Communications. (Source: World Pharma News)
Source: World Pharma News - October 20, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Americans will spend half their lives taking prescription drugs, study finds
An American born in 2019 will spend a larger share of their lifetime taking prescription drugs than being married or receiving an education, according to new research by Jessica Ho, associate professor of sociology and demography at Penn State. She found that American males will spend approximately 48% of their lives taking prescription drugs. The number jumped to 60% for females. (Source: World Pharma News)
Source: World Pharma News - October 19, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New study suggests promising approach for treating pancreatic cancer
A new study carried out in mice, led by Queen Mary University of London, has identified cells that drive the spread of pancreatic cancer and discovered a weakness in these cells that could be targeted using existing drugs. This offers a promising new approach for treating pancreatic cancer.
The research, published in Science Advances and funded by Barts Charity and Cancer Research UK, found that many patients' pancreatic cancer contains cells called amoeboid cells. (Source: World Pharma News)
Source: World Pharma News - October 18, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Drug-delivery technique for brain cancer shows growing promise
A technique developed by University of Texas at Dallas and UT Southwestern Medical Center researchers to deliver medication through the blood-brain barrier has shown promise in a preclinical study for treating glioblastoma, the most common human brain cancer.
The researchers demonstrated the method in mice in a study published online Aug. 15 in Nature Communications. (Source: World Pharma News)
Source: World Pharma News - October 17, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Targeting a coronavirus ion channel could yield new COVID-19 drugs
The genome of the SARS-CoV-2 virus encodes 29 proteins, one of which is an ion channel called E. This channel, which transports protons and calcium ions, induces infected cells to launch an inflammatory response that damages tissues and contributes to the symptoms of COVID-19.
MIT chemists have now discovered the structure of the “open” state of this channel, which allows ions to flow through. (Source: World Pharma News)
Source: World Pharma News - October 16, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
Ahead of this month's CPHI Barcelona - the world's largest pharma event, held at Fira Barcelona (October 24-26th, 2023) - and CPHI & PMEC India to be held at India Expo Centre, Greater Noida, Delhi NCR (November 28-30) key highlights from the CPHI pharma survey are announced. The full findings will be published at CPHI Barcelona as part of the CPHI Annual Report. (Source: World Pharma News)
Source: World Pharma News - October 13, 2023 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
U.S. FDA approves Pfizer & #039;s BRAFTOVI ® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. (Source: World Pharma News)
Source: World Pharma News - October 12, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD 250 million investment will support the production of material required for clinical trials and potential commercial launch of BlueRock Therapeutics' bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson's Disease. (Source: World Pharma News)
Source: World Pharma News - October 11, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
